Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, including orphan tauopathies, Alzheimer’s and Parkinson’s disease.
Products, services, technology
Asceneuron has two clinical-stage small molecule O-GlcNAcase inhibitors in development: OGA inhibitor ASN90 (licensed to Ferrer Pharmaceuticals) for the treatment of progressive supranuclear palsy (PSP) and a potential best-in-class OGA inhibitor, ASN51 for Alzheimer’s disease.
- http://www.asceneuron.com
- asce-contact@asceneuron.com
- Barbara Angehrn, CEO
